| Literature DB >> 26987259 |
Catherine Larochelle1, Timo Uphaus2, Alexandre Prat3, Frauke Zipp4.
Abstract
Prevention of progression in neurological diseases, particularly in multiple sclerosis (MS) but also in neurodegenerative diseases, remains a significant challenge. MS patients switch from a relapsing-remitting to a progressive disease course, but it is not understood why and how this conversion occurs and why some patients never experience disease progression. Do aging and accumulation of neuronal damage induce progression, or do cognitive symptoms and accelerated grey matter (GM) atrophy point to distinct processes affecting networks? This review weighs accepted dogma against real data on the secondary progressive phase of the disease, highlighting current challenges in this important field and directions towards development of treatment strategies to slow or prevent progression of disability.Entities:
Keywords: conversion; multiple sclerosis; neurodegeneration; progression; secondary progressive; senescence
Mesh:
Year: 2016 PMID: 26987259 DOI: 10.1016/j.tins.2016.02.001
Source DB: PubMed Journal: Trends Neurosci ISSN: 0166-2236 Impact factor: 13.837